ATR vs CRL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AptarGroup exhibits strong financial health with a Piotroski F-Score of 8/9, indicating robust fundamentals and consistent profitability. The company trades below its growth-based intrinsic value of $186.14 but at a premium to its Graham defensive value of $77.42, reflecting reasonable valuation given its earnings momentum. Despite solid ROE of 15.62% and low debt/equity of 0.46, insider selling and weak technical trend signal caution. Analysts recommend a 'buy' with a target price of $159.14, implying 26% upside, though recent price performance remains negative over the past year.
CRL presents a contradictory profile characterized by a very weak Piotroski F-Score of 2/9, indicating significant deterioration in fundamental financial health. While the company maintains a strong track record of beating earnings estimates and carries an attractive Forward P/E of 13.76, negative profit margins and declining YoY revenue and EPS growth are concerning. The valuation appears discounted (PEG 0.13), but the bearish technical trend and poor health score offset the bullish analyst consensus. Overall, the stock is a value play contingent on a fundamental turnaround that is not yet evident in the data.
Compare Another Pair
Related Comparisons
ATR vs CRL: Head-to-Head Comparison
This page compares AptarGroup, Inc. (ATR) and Charles River Laboratories International, Inc. (CRL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.